Company / Operating Margin
Ernexa Therapeutics Inc. Operating Margin History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
-2693.1%
FY2025
5-year range
-31080.9% / 0.9%
FY2021-FY2025
Trend
+91.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Margin returned to growth in FY2025 after 2 years of decline, reaching -2693.1%.
Based on SEC 10-K filings.
-2693.1% in FY2025 with a 10-year CAGR of -2674.9%.
Declined from -8.9% to -2693.1% over the past 5 years.
Operating Margin over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -2684.2pp
- 10-Year Change
- -2674.9pp
Key checks
Key Insights
- In FY2025, operating margin increased 91.3% year-over-year.
- Peak operating margin was recorded in FY2019.
- Lowest operating margin in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -2693.1% | +91.3% |
| FY2024 | -31080.9% | - |
| FY2023 | - | - |
| FY2020 | -8.9% | -1123.0% |
| FY2019 | 0.9% | +113.2% |
| FY2018 | -6.6% | +35.5% |
| FY2017 | -10.2% | +63.7% |
| FY2016 | -28.1% | -54.4% |
| FY2015 | -18.2% | -286.6% |
| FY2014 | -4.7% | -6.8% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026